A Johns Hopkins study reveals that anti-VEGF treatments for wet AMD may unintentionally elevate ANGPTL4, a protein that ...
The Valeda Light Delivery System is for the treatment of patients with dry age-related macular degeneration (AMD).
The investigators conducted a randomized controlled trial of 60 patients who underwent monitored anesthesia care sedation for ...
Formosa Pharmaceuticals has announced the completion and top-line results from CPN-303, a phase 3 clinical study of APP13007 ...
The investigators explained that AMN, a rare disease, is characterized by dark reddish, wedge-shaped macular lesions. 2 ...
Robert T. Chang, MD, from Stanford University discusses how large language models are transforming ophthalmology by enhancing ...
Omar Salamanca, MD, staff ophthalmologist, Orbis Flying Eye Hospital, discusses Orbis's tailored glaucoma training programs, which focus on hands-on surgical skills, early detection, telemedicine, and ...
In an interview with David Hutton of Ophthalmology Times, Ash Abbey, MD, discusses the Phase 3 LUGANO trial for EYP-1901 in treating wet age-related macular degeneration. Abbey discusses the trial’s ...
FELIQS plans to conduct a Phase 1b/2 study of FLQ-101 (tROPhy-1 study) both in the US and Japan in the first quarter of 2025.
Dropless cataract surgery eliminates postoperative eye drops, enhancing patient adherence and reducing complications like ...
Researchers receive $6.4 million grant from NEI to seek new treatment for blindness-causing diseases
Rensselaer researchers receive $6.4 million grant from NEI to seek new treatment for blindness-causing diseases.
200 mg of caffeine elevated the blood pressure after 2 hours but did not impact the retinal VD.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback